ABOUT THE TRIAL
The OPTIMAS trial (OPtimal TIMing of Anticoagulation after Stroke) is sponsored by UCL with a grant from the British Heart Foundation.
OPTIMAS is a multi-centre randomised controlled trial of early vs standard, guideline-based timing of anticoagulation with a DOAC in patients with atrial fibrillation and acute ischaemic stroke.
The trial is hoping to recruit 3500 participants over a four year time period. The planned end of recruitment is January 2024.
Chief Investigator: Professor David Werring (UCL)
Eligibility: Adult patients with nvAF and clinical diagnosis of acute ischaemic stroke, eligible for DOAC treatment.
Intervention: Anticoagulation with any DOAC within 4 days of acute ischaemic stroke
Control: Anticoagulation with any DOAC at 7—14 days of acute ischaemic stroke
Key Outcomes: combined incidence of symptomatic ICH, ischaemic stroke and systemic embolism at 90 days; intracranial and major extra-cranial bleeding
Imaging: encouraged but no specific requirements for study entry
Opened to Recruitment: June 2019
Target Sites: >100 in UK
